In the past 12‑18 months, the Growth Factor ELISA Kit market has accelerated through strategic partnerships and technology rollouts. Early 2024 saw Thermo Fisher strike a global partnership with the European Stem Cell Consortium, adding 30 new laboratory customers across Europe. BioTechne’s $210 million acquisition of CellSignal introduced proprietary monoclonal antibodies that lift assay sensitivity by 40 %. In July, Abcam launched a multiplex Growth Factor ELISA platform that quantifies VEGF, FGF‑2, and PDGF‑BB in a 2‑hour workflow, meeting rising demand for high‑throughput screening. The FDA’s revised biomarker‑validation guidance, released mid‑2024, streamlines clinical‑trial kit approvals, encouraging broader adoption. Enterprise labs are increasingly integrating the kits into automated liquid‑handling systems to reduce hands‑on time and improve reproducibility. Meanwhile, a $45 million Series B round funded NeoQuant’s new Singapore manufacturing hub, positioning it for rapid expansion in the Asia‑Pacific region. Additionally, Roche announced a strategic investment in AI‑driven assay design, aiming to launch next‑generation kits by 2026. These moves collectively shape current Growth Factor ELISA Kit industry trends and signal a robust growth trajectory.
